胺对TRPM3的抑制为腺菌症管理提供了潜在的治疗方法
Zhixing Jin1, Yaoming Peng2, He Zhang1
1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215123, People's Republic of China.
过渡性受体潜能 (TRP) 道在腺菌症中发生变化. 在小鼠模型中,primidone治疗通过减少疾病标志物和疼痛来证明治疗潜力,这表明了新的治疗途径.
科学领域:
- 妇科 妇科 妇科 妇科
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 腺肌病是一个妇科病症,其特点是子宫壁中的子宫内膜组织.
- 暂时受体潜能 (TRP) 道与疼痛和炎症有关,但它们在腺菌症中的作用尚未完全理解.
研究的目的:
- 为了研究TRP通道的表达形状在腺菌症患者.
- 为了评估primidone在tamoxifen诱导的腺肌病的小鼠模型上的治疗效果.
主要方法:
- 来自腺菌症患者的人类顺性子宫内膜接受了TRP通道的mRNA分析.
- 免疫组织化学用于检查患者和小鼠的TRPA1,TRPV1和TRPM3表达.
- 泰莫西芬诱导的腺菌症小鼠被用普里米或阿托西班治疗,随后进行行为测试和分子分析.
主要成果:
- 在腺核性子宫内膜的增殖阶段观察到15个TRP通道的mRNA表达增加.
- TRPV1,TRPM3和TRPA1的表达与腺菌症的严重程度相关.
- 在小鼠中,胺治疗显著降低了肌肉膜透和改善了疼痛缓解,受影响的基因在细胞循环途径中得到丰富.
结论:
- 在腺菌症中,TRP通道表达模式发生显著变化.
- 普里米作为一种潜在的治疗药物,有望在治疗腺菌症方面发挥作用.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drugs for Treatment of Constipation-Predominant IBS
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
